Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells
Immune responses to adeno-associated virus (AAV) capsids limit the therapeutic potential of AAV gene therapy. Herein, we model clinical immune responses by generating AAV capsid-specific chimeric antigen receptor (AAV-CAR) T cells. We then modulate immune responses to AAV capsid with AAV-CAR regulat...
Guardado en:
Autores principales: | Motahareh Arjomandnejad, Katelyn Sylvia, Meghan Blackwood, Thomas Nixon, Qiushi Tang, Manish Muhuri, Alisha M. Gruntman, Guangping Gao, Terence R. Flotte, Allison M. Keeler |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/1d3794b4a1154ad0b895efd390f57d2a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Erica L. Heipertz, et al.
Publicado: (2021) -
Serotype-dependent recombinant adeno-associated vector (AAV) infection of Epstein–Barr virus-positive B-cells, towards recombinant AAV-based therapy of focal EBV + lymphoproliferative disorders
por: Elham Ahmadi, et al.
Publicado: (2021) -
Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells
por: Shin Yi Tang, et al.
Publicado: (2021) -
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
por: Cristina Aparicio, et al.
Publicado: (2021) -
Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Sergey Kulemzin, et al.
Publicado: (2021)